About NEOGAP
NEOGAP is a company based in Stockholm (Sweden) founded in 2016. NEOGAP has raised $10.23 million across 4 funding rounds from investors including Okomera, European Union and Eureka Network. NEOGAP offers products and services including pTTL Cell Therapy, PIOR® Technology, and EpiTCer® Technology. NEOGAP operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
- Headquarter Stockholm, Sweden
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neogap Therapeutics Ab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10.23 M (USD)
in 4 rounds
-
Latest Funding Round
$9.76 M (USD), Series A
Feb 11, 2026
-
Investors
Okomera
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NEOGAP
NEOGAP offers a comprehensive portfolio of products and services, including pTTL Cell Therapy, PIOR® Technology, and EpiTCer® Technology.
Personalized therapy that trains immune cells to target cancer cells.
Platform for identifying tumor-specific mutations in cancer research.
Technology for manufacturing cell therapies targeting neoantigens.
Funding Insights of NEOGAP
NEOGAP has successfully raised a total of $10.23M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $9.76 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NEOGAP
NEOGAP has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Okomera, European Union and Eureka Network.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Microfluidic chip device for in vitro cancer testing is developed.
|
Locked | Locked | Locked | |
|
Business management consulting services are offered to clients.
|
Locked | Locked | Locked |
Investor details for NEOGAP
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NEOGAP
Investment portfolio details for NEOGAP
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NEOGAP
Detailed financials for NEOGAP
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neogap Comparisons
Peer comparison for NEOGAP
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NEOGAP
NEOGAP operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
ALX Oncology is focused on advancing cancer treatment therapies.
|
Detailed competitors of NEOGAP
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neogap
Complete news archive for NEOGAP
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NEOGAP
NEOGAP was founded in 2016 and raised its 1st funding round 7 years after it was founded.
NEOGAP is headquartered in Stockholm, Sweden.
NEOGAP is a funded company, having raised a total of $10.23M across 4 funding rounds to date.
NEOGAP was founded in 2016 in Stockholm, Sweden, within the biotechnology sector focused on oncology. Radiopharmaceuticals are developed for cancer treatment, including the pTTL cell therapy product. Neoantigens are targeted through proprietary PIOR technology and patented EpiTCer methods. Immune cells sourced from cancer patients serve as the starting material for these therapies. Operations emphasize personalized approaches to enhance treatment efficacy.
NEOGAP's top competitors include Moderna, BeiGene and Strand Therapeutics.
NEOGAP offers pTTL Cell Therapy, PIOR® Technology, and EpiTCer® Technology.
NEOGAP has 4 investors. Key investors include Okomera, European Union, Eureka Network, and EIC Fund.